Cáncer de mama precoz: el caso de la neoadyuvancia en HER2 positivo - page 34

KRISTINE: Efficacy and HRQoL results
ITT population
TCHP
(n = 221)
KP
(n = 223)
p-value
pCR rate
Overall, % (95% CI)
55.7 (48.8–62.3) 44.4 (37.8–51.2)
0.0155
ER+, %
43.8
35.1
ER–, %
73.2
54.2
BCS rate
, %
52.6
41.7
0.0228
HRQoL
Median time to deterioration
in HRQoL, months*
3.0
4.6
Median time to deterioration
in physical function, months*
2.8
4.9
Hurvitz SA, et al. ASCO 2016
1...,24,25,26,27,28,29,30,31,32,33 35,36,37,38,39,40,41,42,43,44,...47
Powered by FlippingBook